Valuation: Intellipharmaceutics International Inc.

Market Cap 14.06L 12.04L 11.25L 10.32L 19.39L 13Cr 19.77L 1.33Cr 51.93L 6.74Cr 52.81L 51.66L 22Cr P/E 2021
-0.69x
P/E 2022 -0.82x
Enterprise Value 36.49L 31.23L 29.19L 26.76L 50.29L 35Cr 51.29L 3.46Cr 1.35Cr 17Cr 1.37Cr 1.34Cr 58Cr EV / Sales 2021
-
EV / Sales 2022 70.4x
Free-Float
98.24%
Yield 2021 *
-
Yield 2022 -
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.15
5 years 0
Extreme 1.0E-6
0.3
10 years 0
Extreme 1.0E-6
33.5
Manager TitleAgeSince
Director of Finance/CFO - -
Comptroller/Controller/Auditor - 01/04/2007
Corporate Officer/Principal - 01/02/2014
Director TitleAgeSince
Director/Board Member - 01/09/2004
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
-2.81%+1.98%+76.96%+127.73% 1,14100Cr
-2.21%+2.50%+50.38%+55.01% 66TCr
-1.56%+5.25%+26.98%+74.39% 47TCr
+1.20%+1.72%+42.89%+45.78% 37TCr
-0.61%+1.72%+25.21%+41.34% 30TCr
+0.32%+3.30%+2.60%+13.42% 25TCr
-1.95%+4.22%+46.75%+65.66% 24TCr
-1.10%-1.12%-14.91%-52.66% 21TCr
-2.82%+5.57%+21.58%+89.04% 18TCr
Average -0.46%+3.69%+30.94%+51.08% 38.21TCr
Weighted average by Cap. -0.09%+4.31%+44.42%+70.86%

Financials

2021 2022
Net sales - 65.73T 56.26T 52.59T 48.21T 90.6T 62.9L 92.39T 6L 2L 31.5L 2L 2L 1.04Cr
Net income -51.45L -44.04L -41.17L -37.74L -70.92L -49Cr -72.33L -4.88Cr -1.9Cr -25Cr -1.93Cr -1.89Cr -82Cr -28.92L -24.76L -23.14L -21.21L -39.87L -28Cr -40.66L -2.74Cr -1.07Cr -14Cr -1.09Cr -1.06Cr -46Cr
Net Debt 11.45L 10L 9L 8L 15.79L 11Cr 16.1L 1.09Cr 42.29L 5.49Cr 43.01L 42.07L 18Cr 22.42L 19.19L 17.94L 16.45L 30.91L 21Cr 31.52L 2.12Cr 82.79L 11Cr 84.19L 82.35L 36Cr
Logo Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Employees
11
  1. Stock Market
  2. Stocks
  3. IPCIQ Stock